Abstract
Objective To retrospectively analyze the effect of tumor length on the prognosis in stage Ⅱ/Ⅲ esophageal squamous cell carcinoma (ESCC) patients treated with definitive radiotherapy and to evaluate the role of tumor length in clinical stage for non-operative ESCC patients. Methods The data of 2 086 ESCC patients who were treated with definitive radiotherapy from 2002 to 2016 in 10 hospitals (3JECROG) were analyzed. The effect of tumor length on overall survival (OS) was analyzed and stratified analysis of tumor length was done in different stages of ESCC. Results The median OS and median progression-free survival (PFS) time of the whole group were 25.6 months and 18.2 months respectively. The Cox multivariate analysis showed that treatment moda, aga, alinical stage and tumor length were independent prognostic factors. The median, 1-, 3-, and 5-year OS were 28.9 months, 77.3%, 45.0%, and 36.3% versus 21.9 months, 69.9%, 37.9%, and 28.1% for patients with ≤5 cm and patients>5 cm respectively (P 5 cm group (P=0.303). And for stage Ⅲ patienta, ahe median OS were 23.9 and 19.3 months respectively in ≤5 cm group and>5 cm group (P 5 cm group (P<0.001). Conclusions The tumor length was an independent prognostic factor for stage Ⅱ/Ⅲ patients treated definitive radiotherapy. The tumor length may be helpful in clinical staging of ESCa, aspecially for stage Ⅲ and N1. Key words: Esophageal neoplasms/radiotherapy; Tumor length; Clinical stage; Prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
